GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2006

Teva Granted Tentative Approval for Generic Risperdal Oral Solution

  • Teva Pharmaceutical Industries received tentative approval in response to the abbreviated new drug application filed to market the company’s generic version of Janssen’s Risperdal® (Risperidone) Oral Solution, 1 mg/mL. Final approval is expected upon expiry of Risperdal’s patent on December 29, 2007.

    Upon final approval, Teva’s Risperidone Oral Solution will be the AA-rated generic equivalent of Risperdal, indicated for treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder.

    Annual brand product sales in the U.S. were approximately $66 million for the 12-month period, which ended on June 2006, based on IMS data, reports Teva.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?